Mainz, 2017-10-25 – TRON scientific advisor Prof. Dr. Dr. Cornelis J. Melief, Leiden, Netherlands, will be awarded with the degree of an honorary medical doctor. Melief will be awarded for his lifetime achievements as a pioneer of tumor immunology, as well as for his commitment and deserts regarding immunological research in Mainz. Further information about
Was versprechen neuartige personalisierte Krebsimmuntherapien? Wie können Patienten von Ihnen profitieren, und welche Risiken bergen die Behandlungen? Zwei neue Ansätze in der Krebsimmuntherapie sind die CAR-T-Methode und die so genannten Neoantigen-Vakzine. Beide werden gerade getestet und sind sehr vielversprechend. Der regionale Radiosender SWR2 sendete hierzu einen Radiobeitrag in seinem Programm. Einen Mitschnitt sowie ein Transkript
The 12th Mainz Clinical Pathology Seminar will assemble experts from the basic scientific, clinical, biopharmaceutical and pathological fields to give an overview of the exciting developments in cancer immunotherapies.
Among nucleic acid-based delivery platforms, self-amplifying RNA (saRNA) vectors are of increasing interest for applications such as transient expression of recombinant proteins and vaccination. Although saRNA is a promising technology, antigen expression from saRNA is limited by the host cells’ innate interferon response. TRON’s Tim Beissert and colleagues show, in an upcoming issue of Human
Mainz, June 2017 – We are pleased to announce that our close cooperation partner BioNTech has today published an article in Nature Medicine. The paper entitled “Elimination of large tumors in mice by mRNA-encoded bispecific antibodies” reports preclinical data featuring their novel class of mRNA-encoded antibody drugs called RiboMABs® and describes the application of their
Mainz, 20. December 2016 – TRON scientists kick off special issue in Frontiers in Immunology. This is a call for papers to provide an up-to-date overview of current efforts to understand the immunological mechanisms of neoantigen directed T-cell immunity and the attempts to harvest this source of antigens for cancer immunotherapy. Read more about the
Mainz, 23. November 2016 – Wie entstehen Krebszellen? Ist Krebs erblich? Warum ist es so schwer, Krebs zu behandeln/zu heilen und welche neuen Ansätze zur Krebsbehandlung gibt es? Welche Rolle spielt dabei die individualisierte Immuntherapie – und was ist das überhaupt? TRON und BioNTech tragen 11 Fakten über Krebs zu “Wissen im Herzen” bei, eine
Mainz, November 17 – ‘The immune biology of microsatellite instability cancer: Towards a vaccine against HNPCC’, Prof. von Knebel Doeberitz from the Institute of Pathology at the University of Heidelberg will speak in our seminar on Thursday during his visit at TRON.
Mainz, November 10 – ‘Inducing Neoantigens in Therapeutic and Prophylactic Cancer Immunotherapy’, Prof. Eli Gilboa from the Sylvester Comprehensive Cancer Center at the University of Miami will speak in our seminar on Thursday during his visit at TRON.
Mainz, September 29 – ‘Diabetes, beta-cells and reprogramming with mRNA: potential cell-based therapy for diabetes’ Tomáš Koblas of the Institute for Clinical and Experimental Medicine, Prague, will talk at Seminars in Translational Oncology (SITO) during his visit at TRON.
Milwaukee, WI, July 23, 2016 – ‘A message for immunity: Systemic nanoparticle RNA vaccines mimic infection to fight cancer’, The American Society of Gene & Cell Therapy (ASGCT) publishes an author summary of our publication by Lena M. Kranz and colleagues in the renowned scientific journal Nature.
Winchester, UK, September 13th – ” Systemic nanoparticle RNA vaccines mimic infection to fight cancer”, Lena M. Kranz will speak at the 16th International Conference on Progress in Vaccination Against Cancer (PIVAC-16), Session 5.